Inositol for Health & Longevity - Quick Reference Sheet

Inositol for Health & Longevity

Created on 07/09/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Inositol is an inexpensive, well-tolerated compound acting as a messenger for insulin and several hormones. Strongest evidence supports better insulin response and more regular cycles and ovulation in a common hormonal condition, comparable to a standard medication with fewer digestive complaints. Blood-sugar prevention in pregnancy, egg quality, sleep, and mood remain unconfirmed. (Full Review)

Protocol

Dose
4 g/day
Myo-inositol, often with 400 mcg folic acid
Timing
Twice daily
Split morning and evening for stable exposure
Form
Myo-inositol
40-to-1 myo-inositol to D-chiro-inositol ratio
Time to effect
Metabolic markers
8–12 weeks
Insulin and glucose changes become measurable
Cycle & ovulation
3–6 months
Menstrual and ovulatory improvements

Benefits

Contraindications
  • High-dose D-chiro-inositol if pursuing fertility
  • Bipolar disorder
  • Advanced kidney disease (eGFR < 30 mL/min/1.73m²)
Key Interactions
  • Antidiabetic drugs (insulin, sulfonylureas, metformin)
  • Insulin-sensitizing supplements (berberine, alpha-lipoic acid, chromium)

Risk & Side Effects

  • High: Dose-dependent gastrointestinal disturbances
  • Medium: High-dose D-chiro-inositol & reduced oocyte quality
  • Low: Mild neurological effects; theoretical additive blood-sugar lowering
  • Speculative: Mood activation in bipolar disorder; uncertainty at very high doses in pregnancy

Monitoring

Marker Target Why
Fasting insulin 2–5 µIU/mL Most sensitive early marker of insulin resistance
Fasting glucose 75–85 mg/dL Tracks blood-sugar control
HOMA-IR < 1.0 Primary insulin-resistance response marker
HbA1c < 5.3% Average blood sugar over ~3 months
Total & free testosterone Total 15–45 ng/dL (women) Tracks androgen excess in polycystic ovary syndrome
Sex hormone-binding globulin 40–80 nmol/L (women) Rises as insulin falls, lowering active androgens
Triglycerides < 80 mg/dL Metabolic-syndrome marker responsive to insulin sensitization
HDL cholesterol > 60 mg/dL Protective lipid marker that can improve with metabolic gains

Cadence: Baseline, at 12 weeks after starting, then every 6–12 months

Qualitative Assessment

  • Menstrual cycle regularity and predictability
  • Energy levels and reduction of post-meal energy crashes
  • Skin changes related to androgen excess (acne, oily skin)
  • Sleep quality and ease of falling back asleep after waking
  • Mood stability and anxiety levels